IP Library › Patent Application 15587471
Patent Application
App. No. 15/587,471

Sincalide Formulations

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/587,471
Abstract

The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosting gall bladder-related disorders using sincalide formulations.

Claims (23)

1 . A pharmaceutical composition comprising:

(a) a compound of formula

(b) at least one compound selected from the group consisting of:

and

(c) at least one component selected from the group consisting of:

a stabilizer,

a surfactant/solubilizer,

a chelator,

a bulking agent/tonicity adjuster, and

a buffer.

2 . The pharmaceutical composition of claim 1 comprising a compound of formula

3 . The pharmaceutical composition of claim 1 comprising a compound of formula

4 . The pharmaceutical composition of claim 1 comprising a compound of formula

5 . The pharmaceutical composition of claim 1 comprising a compound of formula

6 . The pharmaceutical composition of claim 1 comprising at least two compounds selected from the group consisting of:

7 . The pharmaceutical composition of claim 1 comprising at least three compounds selected from the group consisting of:

8 . The pharmaceutical composition of claim 1 comprising:

9 . A use of the pharmaceutical composition according to claim 1 in a preparation of a medicament for treatment or prevention of a medical condition associated with total parenteral nutrition (TPN).

10 . The use of claim 9 wherein said medical condition is TPN-associated cholestatis.

11 . A use of the pharmaceutical composition according to claim 1 in combination with a hepatobiliary imaging agent for diagnostic imaging of a hepatobiliary system.

12 . The use of claim 11 , wherein the hepatobiliary imaging agent is a 99m Tc-IDA (Iminodiacetic acid) analog.

13 . The use of claim 11 , wherein the hepatobiliary imaging agent is 99m Tc-mebrofenin.

14 . The use of claim 11 for diagnosis of gallbladder diseases and related disorders.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: METCALFE, EDMUND C.; MONTEFERRANTE, JO ANNA; NEWBORN, MARGARET; ROPIAK, IRENE; SCHRAMM, ERNST; WHITE, GREGORY W.; ZODDA, JULIUS P.
To: BRACCO INTERNATIONAL B.V.
Reel/Frame 042251/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: BRACCO INTERNATIONAL B.V.
To: BRACCO SUISSE SA
Reel/Frame 042251/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: BRACCO SUISSE SA
To: BRACCO DIAGNOSTICS INC.
Reel/Frame 042251/0822 →